Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
The VSOP/A group had significantly improved processing speed and attention performance compared to the VE group, and these differences persisted through 6 months postintervention.
Why it matters
This randomized controlled trial in dementia caregivers found that speed of processing training improved processing speed and attention, and at 12 months caregivers reported less negative emotion in response to care recipient symptoms. It tested caregiver outcomes, not prevention or treatment of Alzheimer's disease itself.
-
Patients with CLTI undergoing peripheral vascular intervention from 2017 to 2018 were derived from the Medicare-linked VQI (Vascular Quality Initiative) registry.
Why it matters
In patients with chronic limb-threatening ischemia after peripheral vascular intervention, dementia was among the variables ranked as predictive of 3-year mortality by a machine-learning model. This is about predicting death risk in a vascular disease population, not about treating, curing or preventing Alzheimer's disease.
-
The number of people living with dementia worldwide is growing.
Why it matters
This meta-analysis across several culturally and geographically different cohorts found that total grey matter volume mediated the link between demographics, vascular risk factors, and cognitive decline. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
The prevalence of cognitive impairment, MCI, and dementia among participants aged 60 years and older were 21.48% (95% CI, 19.90-23.10), 15.70% (95% CI, 14.30-17.10), and 5.77 (95% CI, 4.90-6.70), respectively.
Why it matters
This study found that age and education were independently associated with cognitive impairment in older Han Chinese adults, and that some lifestyle factors showed links that disappeared when quantified. It is a cross-sectional study and cannot show cause or effect, so it does not provide evidence for treating, curing, or preventing Alzheimer's disease.
-
The 32 796 872 Medicare beneficiaries in the cohort had a mean (SD) age of 74.0 (12.5) years and included 18 228 513 females (55.6%).
Why it matters
This study found that Medicare Advantage enrollment among beneficiaries with Alzheimer disease and related dementias increased from 24.7% in 2013 to 33.0% in 2018. Beneficiaries with dementia were 1.4 times as likely to disenroll from Medicare Advantage to traditional Medicare compared to those without dementia.
-
In this cross-sectional study of the Medicare population with acute and postacute care use, beneficiaries with ADRD had increasing enrollment in the Medicare Advantage program, proportional to the growth in overall enrollment, but their disenrollment from Medicare Advantage in the following year remained higher compared with beneficiaries without ADRD.
Why it matters
This study found that Medicare beneficiaries with Alzheimer's disease and related dementias left Medicare Advantage for traditional Medicare at a slightly higher rate than those without dementia. It does not test any treatment or prevention for Alzheimer's disease, but it points to a need to understand whether these higher disenrollment rates reflect problems with access or quality of care.
-
These results highlight the need to increase the overall detection rates of MCI and of dementia particularly in socioeconomically disadvantaged groups.
Why it matters
This analysis found that most expected cases of mild cognitive impairment in the Medicare population were not diagnosed, and detection was lower in Black and Hispanic beneficiaries than in non-Hispanic White beneficiaries. This matters because treatment for early-stage disease cannot be given to people who are never detected.
-
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology.
Why it matters
Gives recommendations to help clinicians use lecanemab, approved in the United States for early Alzheimer's disease with confirmed brain amyloid, as safely as possible in everyday practice. It covers monitoring for side effects such as amyloid related imaging abnormalities (ARIA) and infusion reactions, advises that patients who need anticoagulants not receive lecanemab until more data are available, and recommends APOE genotyping because APOE4 carriers are at higher risk for ARIA.
-
of 74,486 decedents (60.5% women; mean age 87.1 years (standard deviation: 7.1)), 82.6% had at least one ED visit in their last year of life.
Why it matters
In this cohort of 74,486 people who died with dementia, 82.6% had at least one emergency department visit in their last year of life. Areas with more nursing home beds were linked to fewer such visits, which the authors say supports investment in nursing home capacity so people can stay in their preferred place of care.
-
Serum lipid traits are associated with cardiovascular disease, but uncertainty remains regarding their associations with dementia.
Why it matters
This study examined whether serum lipid traits were associated with risk of all-cause dementia, Alzheimer's disease, and vascular dementia in a large cohort. It does not show that changing lipid levels prevents dementia, and the findings are observational associations.
-
Medicare Advantage (MA) cares for an increasing proportion of traditional Medicare (TM) patients although, the association of MA on low-value care among hospitalized patients is uncertain.
Why it matters
Among hospitalized patients with advanced dementia, Medicare Advantage enrollment was linked to more invasive mechanical ventilation use and higher 30-day and 365-day mortality than traditional Medicare. This concerns care delivery and outcomes in advanced dementia, not treating, curing, or preventing Alzheimer's disease.
-
= 0.041). Socioeconomic status and residential area are associated with long-term survival in patients with EOD.
Why it matters
In a Korean national database study, socioeconomic status and residential area were associated with long-term survival in patients with early-onset dementia. The authors say this provides a basis for healthcare policy for these patients, but it does not test any treatment, cure, or prevention.
-
Rare variants should only be investigated in users with a family history of early-onset dementia in a first degree relative.
Why it matters
This user manual discusses risk profiling for dementia, noting that rare genetic variants should only be investigated in users with a family history of early-onset dementia and that blood-based biomarkers need further validation. It concerns risk assessment and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Higher prevalence of SCD in SGM adults highlights the importance of ensuring inclusive screenings, interventions, care services, and resources for SGM adults.
Why it matters
Subjective cognitive decline was more common in sexual and gender minority adults than in non-SGM adults, and differences were attenuated after accounting for depression. This concerns who reports memory problems, not treating, curing or preventing Alzheimer's disease.
-
51/100
Significant research gaps remain.
Why it matters
This paper discusses population trends, care interventions, economic costs and health disparities in dementia, noting that incidence is decreasing but advances are uneven. It reports no treatment or cure and identifies gaps in the evidence base.
-
Our results suggest that correlating NLP and ASA with clinician observations is an objective and novel approach to measuring speech and language changes in neurodegenerative disorders.
Why it matters
Variables from automated speech and language analysis were significantly correlated with clinician ratings of speech and language in people with mild cognitive impairment and Alzheimer's dementia. This is about objective measurement of language changes, not about treating, curing, or preventing the disease.
-
The use of new technologies (i.e., mobile ecological momentary assessments [EMAs], activity tracker) in the PENSA study allows the collection of continuous data on lifestyle behaviors (diet and physical activity) and mood, enabling a personalized design as well as an intensive follow-up of participants.
Why it matters
This paper describes the design of a 12-month trial testing whether a personalized multimodal lifestyle intervention combined with epigallocatechin gallate slows cognitive decline in 200 people with subjective cognitive decline who carry the APOE ε4 allele. No results are reported, so it does not yet show whether this approach prevents cognitive decline.
-
Several changes of magnesium (Mg) metabolism have been reported with aging, including diminished Mg intake, impaired intestinal Mg absorption and renal Mg wasting.
Why it matters
This review notes that magnesium deficits have been associated with many conditions including Alzheimer's disease and other dementias, and suggests maintaining optimal magnesium balance may help prevent oxidative stress and chronic age-related conditions. It states plainly that this needs to be demonstrated by future studies.
-
51/100
The most impacting factors on digital divide in our population are the social support networks and the experience with the technology: the presence of a digital native caregiver.
Why it matters
During the COVID-19 lockdown, 74 of 108 patients with cognitive impairment completed a video televisit while 34 could not, and success was higher when a younger caregiver was present. This concerns access to remote care, not treating, curing or preventing Alzheimer's disease.
-
Artificial intelligence (AI) approaches pose a great opportunity for individualized, pre-symptomatic disease diagnosis which plays a key role in the context of personalized, predictive, and finally preventive medicine (PPPM).
Why it matters
This study compared two dementia cohort datasets and found significant differences between them, yet a previously published model trained on one cohort still validated well on the other. It concerns the reliability of AI-based risk prediction tools and does not report a treatment, cure, or prevention.
-
Cognitive impairment is an increasingly recognized major cause of chronic disability and is commonly found in patients with chronic kidney disease (CKD).
Why it matters
This review states that people with chronic kidney disease are at increased risk of dementia and mild cognitive impairment, with brain imaging showing white matter damage and vascular injury. It notes that interventions targeting cardiovascular risk factors appear to have little or no effect on CKD-associated cognitive impairment, suggesting uraemic neurotoxins may be more important.
-
Cigarette smoking is associated with increased risk for myriad health consequences including cognitive decline and dementia, but research on the link between smoking and brain structure is nascent.
Why it matters
In UK Biobank participants, this study assessed the relationship of cigarette smoking with gray and white matter volumes in the brain, controlling for many demographic and health variables. Ever smoking and longer duration were associated with smaller total gray matter, suggesting smoking may affect brain structure.
-
51/100
This study found that a wearable device can be used to differentiate dementia disease subtypes.
Why it matters
A single accelerometer-based wearable differentiated dementia disease subtypes, including Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease dementia, through gait analysis. This is a diagnostic tool and does not treat, cure, or prevent Alzheimer's disease.
-
Functional decline is associated with risk and can be efficiently assessed by participants and study partners (SPs).
Why it matters
This study tested whether functional decline reported by a study partner predicts dementia risk and cognitive decline. It measured associations between Everyday Cognition Scale scores and cognitive outcomes in older adults in ADNI.
-
Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognised as an important comorbidity and complication of diabetes that affects an individual's well-being and diabetes management, and is associated with diabetes treatment-related complications.
Why it matters
This review discusses guidelines recommending screening for cognitive impairment in older people with diabetes and tailoring glucose-lowering treatment to reduce hypoglycaemia and improve adherence. It is about managing diabetes care and does not show that any treatment prevents or cures Alzheimer's disease.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study
- Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
- Placebo interventions for all clinical conditions
- A qualitative inquiry about end-of-life care for people with advanced dementia: “Planning ahead not in reality”
- Hippocampal volume and depression: a meta-analysis of MRI studies
- Falls, Cognitive Impairment, and Gait Performance: Results From the GOOD Initiative
- Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial
- Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia
- Geographic Variation in ADRD Prevalence and Mortality and Their Association with Social Vulnerability across US Counties: A Spatial Epidemiological Analysis Using NORC and CDC SVI Data
- Interactive wearable systems for upper body rehabilitation: a systematic review